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Highlights
 APE1 is overexpressed in colorectal cancer
 The APE1-endonuclease inhibitor (Compound #3) promotes p53 activation in HCT-116
colon cancer cell line.
 Compound #3 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer
cell line.
 Compound #3 affects mitochondrial activity and sensitises cells to genotoxic treatment in
a p53-dependent manner.
 3D organoids derived from colorectal cancer patients are susceptible to Compound #3 in
a p53-status correlated manner.
 Bioinformatics analyses support the hypothesis to target mitochondrial function in cancer
cells through APE1-endonuclease inhibitors.
 Further studies are needed to test the possibility to target the endonuclease activity of
APE1 in colorectal cancer.
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227 Abstract
28 The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as 
29 genomic and microsatellite instabilities. Recently, a contribution of the base excision repair 
30 (BER) pathway in CRC pathology has been emerged. In this context, the involvement of 
31 APE1 in the BER pathway and in the transcriptional regulation of genes implicated in tumor 
32 progression strongly correlates with chemoresistance in CRC and in more aggressive 
33 cancers. In addition, the APE1 interactome is emerging as an important player in tumor 
34 progression, as demonstrated by its interaction with Nucleophosmin (NPM1). For these 
35 reasons, APE1 is becoming a promising target in cancer therapy and a powerful prognostic 
36 and predictive factor in several cancer types. Thus, specific APE1 inhibitors have been 
37 developed targeting: i) the endonuclease activity; ii) the redox function and iii) the APE1-
38 NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The 
39 relationship between APE1 inhibition and p53 is still completely unknown. Here, we 
40 demonstrated that the inhibition of the endonuclease activity of APE1 triggers p53-mediated 
41 effects on cell metabolism in HCT-116 colon cancer cell line. In particular, the inhibition of 
42 the endonuclease activity, but not of the redox function or of the interaction with NPM1, 
43 promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to 
44 genotoxic treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in 
45 a p53-dependent manner. Finally, we demonstrated that 3D organoids derived from CRC 
46 patients are susceptible to APE1-endonuclease inhibition in a p53-status correlated manner, 
47 recapitulating data obtained with HCT-116 isogenic cell lines. These findings suggest the 
48 importance of further studies aimed at testing the possibility to target the endonuclease 
49 activity of APE1 in CRC.
50
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353 1. Introduction
54 Colorectal cancer (CRC) is considered the third most common cancer and the fourth most 
55 common cause of cancer-related death worldwide [1]. CRC is a multistep process involving 
56 a series of histo-morphological and genetic changes, that accumulate over time in the 
57 epithelial layer of the intestinal tract. Interestingly, genetic and epigenetic modifications lead 
58 to the activation of oncogenes and/or the inactivation of tumor suppressor genes, as 
59 formulated by Volgestein and Fearon [2,3]. Both genetic and environmental factors are 
60 essential in the etiology of the disease. About 70% of CRC patients suffer from a sporadic 
61 form, whereas 10-30% present a familial predisposition and only 5-7% exhibit an inherited 
62 trait [4]. However, the most common, often overlapping, mechanisms involved in the 
63 pathogenesis of CRC are represented by the chromosome and microsatellite instabilities, 
64 the CpG island methylator phenotype and the deletion of the long arm of chromosome 18 
65 [1,5]. In the landscape of chromosome instability, the most common mutations occur in 
66 specific tumor suppressor genes (e.g. APC, PTEN, SMAD4, TGFBR2, TP53) or oncogenes 
67 (e.g. BRAF, KRAS, PIK3CA). Recently, the involvement of DNA repair genes has been 
68 demonstrated to be associated with the pathogenesis of CRC [6–8]. In particular, both 
69 endogenous (e.g. metabolic activity of the cells) and exogenous factors (e.g. food intake) 
70 are involved in DNA damage, which requires the activation of the DNA repair mechanisms. 
71 In particular, the base excision repair (BER) pathway is involved in repairing DNA chemical 
72 modifications, such as deamination, oxidation, and alkylation [9]. Interestingly, BER has 
73 been found altered in CRC, as demonstrated by the presence of single nucleotide 
74 polymorphisms (SNPs) in several BER genes including DNA glycosylases, 
75 apurinic/apyrimidinic endonuclease 1 (APE1) and DNA Polymerase  (Pol ) [10]. In BER, 
76 APE1 cleaves the DNA phosphodiester backbone on the 5′ side of an abasic 
77 apurinic/apyrimidinic (AP) site, previously produced by the action of damage-specific 
78 glycosylases, generating a nick in the DNA and leaving 3′ hydroxyl and 5′ dRP free termini, 
79 which are processed and replaced by a correct nucleotide by Pol  [11]. Recent molecular 
80 snapshots of the endonuclease-reaction clearly defined the APE1 catalytic mechanism of 
81 action [12]. The catalytic site of the enzymes involves a Mg2+ ion coordinated by Asp70, 
82 Glu96 and a water molecule in contact with non-bridging oxygen of the phosphate. 
83 Additionally, the nucleophilic water is in position for in-line attack of the phosphorus atom 
84 and is coordinated by Asn212 and Asp210. APE1 is also endowed of an exonuclease activity 
85 through the removal of 3’ end groups of a mismatched or DNA damaged bases to generate 
86 substrates that are processed by the downstream repair enzymes [13]. Recently, we 
87 demonstrated that APE1 plays an important role in the recognition and processing of ribose 
88 monophosphate AP sites and oxidized ribonucleotides embedded in DNA through a 
89 classical AP endonuclease activity and a nucleotide incision repair (NIR) activity, 
90 respectively [14].
91 As widely described, APE1 is implicated in cancer gene expression regulation due to its role 
92 as a redox co-activator of several transcription factors, such as Egr-1, NF-κB, p53, STAT3, 
93 HIF-1α, CREB, AP-1, and Pax-5/8 [15]. APE1 is considered as a unique nuclear redox-
94 signaling factor bearing seven Cys residues. Three of the Cys residues, C65, C93, and C99, 
95 are essential for its redox activity, that involves a redox cycle through the potential formation 
96 of intermolecular disulfide bonds with the protein target [16–20]. While C65 acts as the 
97 nucleophilic cysteine, C93 and C99 likely play roles in resolving disulfide bonds that are 
98 formed in APE1 upon oxidation. Structural studies demonstrated that APE1 exists in both 
99 native and partially unfolded conformations, controlled by Thioredoxin (TRX) [16], in which 
100 the partially unfolded state of APE1 represents the redox active intermediate of the enzyme.
101 Recently, it has been demonstrated that APE1 is not only involved in DNA repair 
102 mechanisms and transcriptional regulation, but also in miRNA metabolism [21]. 
103 Furthermore, the interaction between APE1 and Nucleophosmin (NPM1) is essential for the 
104 subcellular localization of APE1 modulating its endonuclease activity [22]. Interestingly, this 
4
5105 interaction was found altered in ovarian cancer promoting tumor aggressiveness and 
106 resistance. Finally, it has been demonstrated that in the majority of cases, there is a positive 
107 correlation between upregulated expression of APE1 and the development of several 
108 tumors, such as: colon [23,24], breast [25], hepatic [26], prostate [27], pancreatic [28], 
109 ovarian [29], lung cancers [30], leukemias [31] and many others [32]. Furthermore, APE1 
110 overexpression is associated with the onset of chemoresistance phenomena [22]. For these 
111 reasons, APE1 is considered a promising prognostic and predictive biomarker [33] and 
112 several strategies have been developed to inhibit its functions in cancer cells [34], leading 
113 to the development of ongoing clinical trials. 
114 In recent years, a great effort has been put in the development of specific inhibitors targeting 
115 the different functions of APE1, i.e. Compound #3, APX2009, Spiclomazine, Fiduxosin and 
116 SB206553. Compound #3 blocks the endonuclease activity of APE1 acting as a competitive 
117 inhibitor by binding the active site of the enzyme and consequently leading to a decrease of 
118 APE1-DNA complex formation in a dose-dependent manner [35]. The inhibition promotes, 
119 in turn, an increase of the unrepaired AP sites accumulation in genomic DNA, that, in 
120 combination with an alkylating agent treatment, such as methyl methanesulfonate (MMS), 
121 induces high levels of cellular death [36,37]. APX2009, an APE1 specific redox inhibitor, is 
122 the second generation molecules of the drug APX3330, previously named E3330 [38]. 
123 APX3330 inhibits the activator function of APE1 on different transcription factors such as 
124 NF-B, AP-1, HIF-1 and STAT3 [18,39,40]. In particular, APX3330 increases disulfide bonds 
125 involving C65 and/or C93 residues in APE1, impairing its redox activity [41]. APX3330 
126 recently completed cancer phase I clinical trials with demonstrated safety, response and 
127 APE1 target engagement [42,43]. Finally, Spiclomazine, Fiduxosin, and SB206553 
128 molecules inhibit the interaction of APE1 with NPM1, a protein involved in rRNA biogenesis, 
129 by directly binding to the N-terminal domain of APE1. We demonstrated that these inhibitors 
130 alter the localization and the endonuclease activity of APE1, but not the rRNA maturation 
131 [22] and induce apoptosis in different tumor cell lines [22,44]. To our knowledge, only one
132 study investigated the ability of the APE1-redox inhibitor (APX3330) to affect colon cancer 
133 stem cells (CCSCs) growth in vitro and to enhance the effect of the chemotherapeutic agent 
134 5-Fluorouracil (5-FU) in CCSCs xenograft mice [23]. Thus, the importance of exploring the
135 effect of different APE1 inhibitors in CRC models is apparent. Here, we used the well-known 
136 HCT-116 colon cancer cell model, to explore the relevance of p53 upon APE1 inhibition, 
137 and extended our findings using a 3D organoid cultures model derived from CRC affected 
138 patients.
139 Due to the intricate mechanisms that characterize the CRC etiology, research has focused 
140 on personalized precision medicine of CRC. The generation of patient-derived 3D tumor 
141 organoids will greatly enhance our understanding of the disease complexity and the 
142 heterogeneity in order to develop patient-specific therapies [45]. Organoids have a special 
143 property to mirror the key-features of the original patient’s tissue [46], representing an ideal 
144 tool to develop patient-specific therapies by performing drug screenings.
145 Similarly to APE1, the well-known tumor suppressor gene TP53 has been found altered in 
146 most tumors [47]. The wild-type p53 protein is a transcription factor involving in cell cycle 
147 arrest, senescence and apoptosis, besides being a key player in the DNA Damage 
148 Response (DDR) to single-strand breaks (SSBs) and double-strand break (DSBs) 
149 accumulation. Among all the mutated genes promoting CRC, p53 has an important role [48]. 
150 Indeed, loss of p53 function stimulates the development of the late stage of CRC and is 
151 associated with poor prognosis [49]. p53 plays a role not only as a modulator of the cell 
152 cycle to guarantee genome stability, but it is also directly involved in the activation of proteins 
153 that are associated with DNA repair processes [50]. In particular, it has been demonstrated 
154 that p53 prevents genomic instability through a BER gene expression regulation [51]. 
155 Importantly, p53 regulates DNA glycosylases (OGG1 and MUTYH) [52,53], APE1 [54,55], 
156 Pol β [56] expression and acts as a transcriptional repressor of DNA polymerase δ [57]. 
6
7157 However, it is unknown whether p53 is part of DDR starting from AP sites accumulation as 
158 a consequence of APE1 inactivation or inhibition. The present study was aimed at 
159 addressing this issue. Furthermore, data on whether APE1 inhibitors may affect cell viability 
160 of colon cancer cells through p53-induced cell response are the focus of the work presented 
161 here.
162
163 2. Materials and methods
164 2.1. Cell cultures. HCT-116 p53+/+ and HCT-116 p53-/- (ATCC®) cells were grown in 
165 Dulbecco’s modified Eagle’s medium (EuroClone, Milan, Italy) supplemented with 10% fetal 
166 bovine serum (EuroClone). CH12F3+/+/∆ and CH12F3∆/∆/∆ cells were grown in RPMI 1640 
167 (EuroClone) supplemented with 10% fetal bovine serum (EuroClone), 1X non Essential 
168 Amino Acids (EuroClone), 1 mM Sodium Pyruvate (EuroClone), 25 mM HEPES (EuroClone) 
169 and 50 μM β-mercaptoethanol (Promega, Madison, WI, USA). OCI-AML2 cells were grown 
170 in α-MEM (Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum 
171 (EuroClone). HCC70 cells were grown in RPMI 1640 (EuroClone) supplemented with 10% 
172 fetal bovine serum (EuroClone). All culturing media were also supplemented with 2 mM 
173 GlutaMAX (EuroClone), 100 U/ml penicillin and 10 µg/ml streptomycin (EuroClone).
174
175 2.2. Human tissues. Colonic tissues were obtained upon surgical resection from the 
176 University Hospital Santa Maria della Misericordia of Udine. All patients were diagnosed with 
177 colorectal cancer. This study was approved by the ethical committee of University Hospital 
178 Santa Maria della Misericordia of Udine (CEUR-2017-PR-048-UNIUD) and all samples were 
179 obtained prior to informed consent. 
180
181 2.3. Organoid culture. The generation of patient-derived tumor organoids was performed 
182 as described by [58] with some modifications. Tumor intestinal tissue was washed with ice-
183 cold PBS supplemented with 100 U/ml penicillin and 10 µg/ml streptomycin (EuroClone) 
184 several times. Tumor tissue was homogenized with scissors and then digested with 0.26 
185 U/ml Liberase (Sigma-Aldrich, St. Louis, MO, USA) in basal medium, composed of 
186 Advanced DMEM/F12 (Life Technologies, Carlsbad, CA, USA) supplemented with 2 mM 
187 Glutamax (Life Technologies), 10 mM HEPES (Life Technologies), 100 U/ml penicillin and 
188 10 µg/ml streptomycin (EuroClone) complemented with 100 μg/ml Primocin (InvivoGen, 
San 8
9189 Diego, CA, USA) and 10 µM Y-27632 (Abcam, Cambridge, UK) for 1 h at 37 °C shaking at 
190 250 rpm. The resulting fraction was passed through a 100-mm cell strainer. The filtered 
191 solution was centrifuged at 1,200 rpm for 5 min at 4°C. The cell pellet was resuspended with 
192 Red Blood Cell (RBC) Lysis Buffer (BioLegend, San Diego, CA, USA) and incubated for 10 
193 min at room temperature (RT) in the dark. RBC buffer was neutralized adding basal medium 
194 complemented with 10% fetal bovine serum (BioWest, Nuaillé, France). The resulting 
195 solution was centrifuged at 1,200 rpm for 5 min at 4°C and the cell pellet was resuspended 
196 with 3 ml of basal medium. Cells were counted with a Burker chamber and 200,000 cells/10 
197 μl were mixed with 20 μl of Matrigel and 30 μl drop was plated in a single well of 24-well. 
198 After polymerization of Matrigel (Corning®, Corning, NY, USA) for 10-15 min at 37°C, 500 
199 µl of culture medium was added. Tumor organoids were cultured in basal medium containing 
200 1X B27 (Life Technologies), 1.15 mM N-acetylcysteine (Sigma-Aldrich), 10 mM 
201 Nicotinamide (Sigma-Aldrich), 10 nM Gastrin I (Tocris Bioscience, Bristol, UK), 10 nM 
202 Prostaglandin E2 (Sigma-Aldrich), 500 nM A83-01 (R&D System, Minneapolis, MN, USA), 
203 50 ng/ml mEGF (PeproTech, London, UK), 3 µM SB202190 (Sigma-Aldrich), 10% Noggin 
204 Conditioned Medium, 20% R-Spondin1 Conditioned Medium, 10 µM Y-27632 (Abcam) and 
205 100 μg/ml Primocin (InvivoGen). The medium was refreshed every two/three days. Tumour 
206 organoids were passaged 1:4 every one/two weeks.
207
208 2.4. Treatments. Compound #3 was kindly provided by the National Center for Advancing 
209 Translational Sciences. APX2009 was kindly provided by Professor Mark R. Kelley (Indiana 
210 University, School of Medicine). Fiduxosin, SB206553, Spiclomazine were purchased as 
211 previously described [22]. All compounds were solved in dimethyl sulfoxide (DMSO). IC50 
212 values were calculated using Combenefit 2.021 Software.
213
214 2.5. RNA interference. One day before transfection, cells were seeded in 60-mm plates at 
215 a density of 600,000 cells per plate. Cells were then transiently transfected with 100 pmol 
216 siRNA APE1 5 -ʹUACUCCAGUCGUACCAGACCU-3  ʹor the scramble control siRNA 5 -ʹ
217 CCAUGAGGUCAUGGUCUGdTdT-3  ʹ (Dharmacon, Lafayette, CO, USA) using 
218 DharmaFECT reagent (Dharmacon). After 72 h upon transfection, cells were collected and 
219 whole cell extracts were prepared.
220
221 2.6. Preparation of the cell extracts and protein quantification. For the preparation of 
222 whole cell lysates, 200,000 HCT-116 cells were plated on 6-well plates and, the following 
223 day, cells were treated with Compound #3 or APX2009. After 48 h cells were collected by 
224 trypsinization and centrifuged at 250 x g for 5 min. The supernatant was removed, and the 
225 pellet was washed once with PBS and then centrifuged again as described before. Cell 
226 pellet was resuspended in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 
227 mM EDTA, 1% w/v Triton X-100 supplemented with 1 mM protease inhibitor cocktail (Sigma-
228 Aldrich), 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF and 1 mM 
229 Na3VO4 for 30 min at 4 °C. After centrifugation at 13,000 rpm for 20 min at 4 °C, the 
230 supernatant was collected as a whole cell lysate. The protein concentration was determined 
231 by using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA). 
232
233 2.7. Antibodies and Western blotting analysis. For Western blotting analyses, whole cell 
234 lysates were prepared and 30 μg of proteins were resolved on 12% SDS–PAGE, transferred 
235 onto nitrocellulose membranes (Schleicher & Schuell Bioscience, Keene, NH, USA) and 
236 incubated with antibodies for p53 1:1000 (#sc-126, Santa Cruz Biotechnology, Dallas, TX, 
237 USA), APE1 1:1000 (#NB-100116, Thermo Fisher Scientific, Waltham, MA, USA), p21 
238 1:1000 (#2947, Cell Signaling Technology, Danvers, MA, USA) and actin 1:2000 (#A2066, 
239 Sigma-Aldrich). The corresponding secondary antibodies labelled with IR-Dye (goat 
anti-10
240 rabbit IgG IRDye 680 and goat anti-mouse IgG IRDye 800, LI-COR Biosciences, Lincoln, 
241 NE, USA) were used (1:10,000). Blots were developed by using the NIR Fluorescence 
242 technology (LI-COR Biosciences). Images were acquired and quantified by using an 
243 Odyssey CLx Infrared Imaging System (LI-COR Biosciences). 
244
245 2.8. Metabolic activity. Metabolic activity of HCT-116 cell lines was measured through the 
246 MTS CellTiter 96 AQueous One Solution Cell Proliferation Assay and through RealTime-
247 Glo™ MT Cell Viability Assay (Promega) according to the manufacturer's instructions. In 
248 details, 5,000 cells were plated on transparent or black 96-well plates, as needed, and the 
249 day after, cells were treated with the indicated drugs for 48 h. Metabolic activity of CH12F3 
250 cell lines was measured with CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
251 (Promega) according to the manufacturer's instructions. In details, 10,000 cells were plated 
252 on black 96-well plates and the day after cells were treated with increasing amounts of 
253 Compound #3 or APX2009 at the indicated concentrations for 48 h. Metabolic activity of 
254 patient-derived tumor organoids was measured through the RealTime-Glo™ MT Cell 
255 Viability Assay (Promega) according to the manufacturer's instructions. In this case, 3,000 
256 cells derived from tumor organoids were plated together with Matrigel on black 96-well plates 
257 and incubated for three days for allowing the generation of the organoids. Tumor organoids 
258 were treated with increasing amounts of Compound #3 for 48 h. For metabolic assay, Y-
259 27632 was removed from the culture medium.
260
261 2.9. AP sites measurements. For the AP sites measurements, 200,000 HCT-116 cells 
262 were plated on 6-well plates and, the following day, cells were treated with Compound #3. 
263 After 48 h, genomic DNA was extracted from the collected cells using QIAamp DNA Mini Kit 
264 (Qiagen, Hilden, Germany), and concentration and purity were determined by NanoDrop 
265 Microvolume Spectrophotometer (Thermo Fisher Scientific). Samples of 100 µg/ml 
of 11
266 genomic DNA were analyzed to quantify abasic sites in DNA using the DNA Damage 
267 Quantification Kit -AP Site Counting- (Dojindo Molecular Technologies, Kumamoto, Japan) 
268 according to the manufacturer’s instructions.
269
270 2.10. Comet assay analysis. The comet assay was performed as previously described [59]. 
271 Specifically, 25,000 cells were plated on 24-well plates and the day after cells were treated 
272 with 0.5 μM Compound #3. After 48 h, cells were collected and mixed with low melting point 
273 agarose at 37 °C, and the mixture was applied to a agarose pre-coated glass coverslip to 
274 form a thin layer. Cold lysis buffer was added to lyse cells at 4 °C. After 1 h, the glass 
275 coverslip was moved into alkaline electrophoresis buffer for 30 min to unwind DNA. 
276 Electrophoresis was carried out at 25 V and 300 mA for 30 min. The glass coverslip was 
277 washed with neutralizing buffer for three times and stained by Sybr Gold 1X (Thermo Fisher 
278 Scientific) for 30 min in dark. Comets were recorded by laser scanning confocal microscope 
279 (LEICA TCS SP2, Leica Microsystems, Wetzlar, Germany). The tail moment was analyzed 
280 for 100 cells at random by OpenComet software.
281
282 2.11. Quantitative real-time reverse transcriptase-PCR. For RNA extraction, 200,000 
283 HCT-116 cells were plated on 6-well plates and, the following day, were treated with 
284 Compound #3 or APX2009. After 48 h, total RNA was extracted from the collected cells 
285 using the NUCLEOSPIN RNA II (MACHEREY-NAGEL GmbH & Co., Duren, Germany). The 
286 quality of the RNA samples was tested on an agarose gel. Then, single-strand cDNA was 
287 obtained from 1 μg of purified RNA using SensiFAST cDNA Synthesis Kit (Bioline Meridian 
288 Bioscience, Cincinnati, OH, USA). qRT-PCR was performed using SensiFAST SYBR No-
289 ROX Kit (Bioline Meridian Bioscience) and a CFX96 Real-Time System (Bio-Rad). Each 
290 sample analysis was performed in triplicate. Samples without template and without reverse 
291 transcriptase were used as negative control,. The cycling parameters contemplate a first 
12
292 denaturation at 95 °C for 10 s and then 40-cycles of annealing/extension at 60 °C for 30 s. 
293 In order to verify the specificity of the amplification, a melting-curve analysis was performed, 
294 immediately after the amplification protocol. Relative gene expression was calculated with 
295 the 2-ΔΔCt method. The sequences of the primers used are the following: APEX1 For 5’-
296 CCTGGACTCTCTCATCAATACTGG-3’, APEX1 Rev 5’- 
297 AGTCAAATTCAGCCACAATCACC-3’, BIRC5 For 5 -ʹ ACCGCATCTCTACATTCAAG-3 ,ʹ 
298 BIRC5 Rev 5 -ʹCAAGTCTGGCTCGTTCTC-3 ,ʹ DNA polδ For 5’-
299 GCTCCGCTCCTACACGCTCAA-3’, DNA polδ Rev 5’-GTCTGGTCGTTCCCATTCTGC-3’ 
300 and Actin For 5 -ʹCGCCGCCAGCTCACCATG-3 ,ʹ Actin Rev 5 -ʹ
301 CACGATGGAGGGGAAGACGG-3 .ʹ
302
303 2.12. Caspases activity assay. The activities of caspases 3/7 were examined via a 
304 fluorescence-based assay using Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega) 
305 according to the manufacturer's instructions. In details, 5,000 cells were plated on white 96-
306 well plates and the day after cells were treated with increasing amounts of Compound #3 or 
307 APX2009 for 48 h.
308
309 2.13. Cell Mito Stress test. Analyses of the mitochondrial function of HCT-116 cells were 
310 performed by using XFe Extracellular Flux Analyzer (Seahorse, Agilent Technologies, Santa 
311 Clara, CA, USA) as previously described [60]. In details, 5,000 cells were seeded and 
312 cultured in XF Cell Culture Microplates (Agilent Technologies). Before the measurements, 
313 the culture medium was removed from each well and replaced by 500 μl of Seahorse XF 
314 Base Medium (Agilent Technologies), pre-warmed at 37 °C and supplemented with 10 mM 
315 glucose (Sigma-Aldrich), 1 mM pyruvate (EuroClone), 2 mM glutamine (Sigma-Aldrich), at 
316 pH 7.4. Cells were incubated in a CO2-free incubator at 37 °C for 1 h and OCR (oxygen 
317 consumption rate) was detected under basal conditions. The following compounds were 
13
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318 prepared at appropriate concentrations for each injection port to reach the final 
319 concentration of 0.5 μM oligomycin A, 0.5 μM FCCP, 1 μM rotenone and 1 μM antimycin A 
320 (Sigma-Aldrich). Volumes of respectively 56, 62, 69 and 73 μl of compounds were added to 
321 each injection port. Then, after a 3-min pause, 3 response measurements were taken 
322 between each addition. OCR values were normalized to the protein content (μg) of each 
323 well obtained by the Bradford method.
324
325 2.14. Immunofluorescence. Patient-derived tumor organoids were grown on a slide and 
326 fixed in 4% paraformaldehyde for 20 min at 37°C, then washed with PBS 1X, treated with 
327 0.1 M glycine in PBS 1X for 10 min and permeabilized with 0.5% Triton X-100 in PBS 1X for 
328 5 min. After washing with PBS 1X and blocking for 1 h with 1% BSA, 10% FBS, 0.5% Triton 
329 X-100 in Washing Buffer (10 mM Tris HCl pH7.4, 150 mM NaCl and 0.01% Tween 20)
330 organoids were incubated with primary antibodies diluted in blocking solution o/n at 4°C. 
331 After several washes in PBS 1X, organoids were incubated with labeled secondary 
332 antibodies for 2 h at RT. F-actin was stained with 0.165 μM Alexa FluorTM 594 Phalloidin 
333 (Thermo Fisher Scientific) for 20 min at RT. For nuclear staining, organoids were incubated 
334 with 14.3 mM DAPI (Thermo Fisher Scientific) for 5 min at RT. Organoids were washed and 
335 mounted with Mowiol mounting medium. The following antibodies were used: anti-Ki67 
336 1:200 (#AB92742, Abcam), anti-OLFM4 1:200 (#14369S, Cell Signaling Technology), anti-
337 E-Cadherin 1:50 (#610404, BD Biosciences, San Jose, CA, USA) and anti-Lysozyme 1:200
338 (#A009902-2, Agilent Technologies). For detection, Alexa Fluor-488 (#711-546-152 and 
339 #715-546-150 Jackson ImmunoResearch, Ely, UK) antibodies were used. Fluorescent 
340 images were collected using a laser scanning confocal microscope (LEICA TCS SP8, Leica 
341 Microsystems). Brightfield images were collected using a microscope (LEICA MC170 HD, 
342 Leica Microsystems).
343
344 2.15. Library preparation and next-generation sequencing. Genomic DNA from tumor 
345 organoid was extracted using the QIAamp DNA Mini Kit (Qiagen) and quantified by using 
346 the Quant-iT™ PicoGreen™ dsDNA Assay Kit (LifeTechnologies). Briefly, barcoded 
347 libraries were generated from 50 ng of DNA per sample (N=3) using the Ion AmpliSeq 
348 Library Kit Plus (Thermo Fisher Scientific) and two premixed pools of 952 primer pairs 
349 (Thermo Fisher Scientific), according to manufacturer’s instructions. Clonal amplification of 
350 libraries was performed by emulsion PCR on an Ion Chef Instrument. The prepared libraries 
351 were then sequenced on an Ion S5 GeneStudio Sequencer using a Ion 530 Chip and the 
352 Ion 510/520/530 kit–Chef (all Thermo Fisher Scientific).
353
354 2.16. Data analysis and Variant prioritization. We analyzed data using Variant Caller 
355 v5.10 (Thermo Fisher Scientific). Variant caller format files were annotated with Ion Reporter 
356 5.10 (Thermo Fisher Scientific) and wANNOVAR. Somatic variants were called when a 
357 position was covered at least 100X. We set the clinical sensitivity of point mutations and 
358 indels at 5%. Variant prioritization for TP53 was based on population frequency, quality 
359 values and functional consequences. Synonymous variants were excluded. Variants were 
360 filtered based on their frequency ExAC datasets (http://exac.broadinstitute.org) and on 
361 clinical associations (ClinVar database) (https://www.ncbi.nlm.nih.gov/clinvar). 
362
363 2.17. Bioinformatics analysis. Analysis of APEX1 gene expression in colon cancer was 
364 performed through TCGA data retrieval from cbioportal and CMS class information were 
365 accessed from the original Consensus Molecular Stratification of colon cancer. Differential 
366 gene expression analysis was conducted by Mann Whitney test. APE1 interactors analysis 
367 in colon cancer was performed using the differential gene expression results from TCGA 
368 and normal datasets (GTEX data) for the genes encoding the interacting partners of APE1 
369 for colon cancer (COAD). Data was obtained via the GDC data portal hub 
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370 (https://portal.gdc.cancer.gov/, last accessed July 2018). The RUVSeq package inside the 
371 R/Bioconductor environment was used to eliminate the batch effect coming from the 
372 combination of two data sources [61]. In order to better estimate the differentially expressed 
373 genes between the tumor and the normal corresponding datasets, we obtained “in-silico 
374 empirical” negative controls, i.e., the least significantly DE genes based on a first-pass DE 
375 analysis performed prior to RUVg normalization [61]. Differentially expressed genes 
376 (multiple correction adjustment using the Benjamini-Hochberg method, p<0.05; absolute log 
377 fold change difference≥1) were used to perform enrichment and survival analyses. 
378 Enrichment analysis of the DE genes was performed using the DAVID functional annotation 
379 tool based on GO biological process and cellular component terms [62]. For the survival 
380 analysis, Kaplan-Meier plots were drawn using the RTCGA Bioconductor package [63], 
381 which uses maximally selected rank statistics (maxstat) to determine the optimal cutpoint 
382 for continuous variables. Division of the samples was done within the 30-70% percentile 
383 range of gene expression by the optimal cutpoint value. The Benjamini-Hochberg method 
384 was used for p-value correction of Kaplan-Meier plots.
385
386 2.18. Statistical analyses. All reported values are represented as the mean ± SD or mean 
387 ± SEM of at least three biological replicates. Statistical analyses were performed using the 
388 Student’s t-test. P<0.05 was considered as statistically significant.
389
390 3. Results
391 3.1. APE1 is overexpressed in colorectal cancer and the inhibition of its endonuclease 
392 activity triggers p53-mediated effects on cell metabolism
393 APE1 overexpression is correlated with tumor progression of many cancers, but little 
394 information is available on colorectal cancer (CRC) [23,24,64]. In order to further determine 
395 the involvement of APE1 in CRC, we took advantage of the information available from TCGA 
396 data sets of CRC. By performing differential gene expression (DEG) analysis on the TCGA 
397 COAD RNA-seq V2 data, we compared the expression profile of the four consensus 
398 molecular subtypes (CMS) of CRC versus normal control samples [PMC4636487]. The DEG 
399 was computed by the non-parametric Mann Whitney test. A significant upregulation of the 
400 APEX1 gene in the four CMS classes was identified compared to the normal one (Fig. 1A) 
401 (p-value=1.7e-15, 4e-11, 7.2e-14, 3.5e-11, for the CMS class 1-4, respectively), however there 
402 was no significant difference between the CMS classes analysed. These data demonstrate 
403 that APE1 is generally overexpressed in CRC, supporting the hypothesis that it could 
404 represent a novel target for the treatment of this cancer type. 
405 We analyzed the effects of APE1 inhibition on colon cancer cell lines using a number of 
406 APE1 specific small molecule inhibitors: Compound #3, which blocks APE1-endonuclease 
407 activity thus leading to genome instability [35]; APX2009, which inhibits APE1-redox 
408 function, leading to cell-cycle arrest and apoptosis in different cancer cell models [38], and 
409 Fiduxosin, SB206553 and Spiclomazine, as inhibitors of the well-known interaction between 
410 APE1 and NPM1, leading to an alteration of the APE1-endonuclease activity and to 
411 apoptosis in different tumor cell lines [22,44]. A schematic representation of the APE1-
412 inhibitors used in this study is shown in Fig. 1B. 
413 To determine the p53 contribution in APE1 inhibitors induced effects, we took advantage of 
414 the well-known HCT-116 p53+/+ and HCT-116 p53-/- isogenic colon cancer cell lines, which 
415 are wild-type and knock-out for p53 gene expression, respectively [65] (Fig. 1C, top left 
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416 panel). Experimentally, HCT-116 cells were treated with increasing concentrations of 
417 different APE1 inhibitors for 48 hours. The metabolic activity of viable cells was measured 
418 by using the MTS assay, a colorimetric assay which measures the reduction of MTS 
419 tetrazolium compound into formazan in mitochondrial metabolically active cells. The 
420 treatment with the APE1-endonuclease inhibitor Compound #3 demonstrated that HCT-116 
421 p53+/+ cell line was significantly more sensitive, at the doses of 0.25 µM and 0.5 µM, than 
422 HCT-116 p53-/- (Fig. 1C, top in the middle panel and Table 1 for IC50 values). In order to 
423 understand if the inhibition of APE1-redox activity could have some effects on HCT-116 cell 
424 lines, we treated cells with the APX2009 compound. We did not find a significant difference 
425 between HCT-116 p53+/+ and HCT-116 p53-/- cell metabolism upon APX2009 treatment, 
426 even if a mild effect can be observed (Fig. 1C, top right panel and Table 1 for IC50 values). 
427 Similarly, no significant differences, between the two cell lines, were found when inhibitors 
428 of APE1 and NPM1 interaction were used, with Fiduxosin being the most toxic for both cell 
429 lines (Fig. 1C, bottom panel and Table 1 for IC50 values). These findings were in agreement 
430 with the presence of no significant difference in the expression levels of both APE1 and 
431 NPM1, as measured at the mRNA and protein levels (Fig. S1A, B). Moreover, to further 
432 confirm the differential effect of Compound #3 and APX2009 on cell metabolism of HCT-116 
433 p53+/+ and HCT-116 p53-/- cell lines, we performed a luminescence-based metabolic assay 
434 (RealTime-Glo). Compared to MTS assay, previously used, RealTime-Glo is a more 
435 sensitive assay based on the measurement of the reducing potential of mitochondrial 
436 metabolic active cells, considering the luminescent signal produced from the reduction of 
437 the substrate used by the luciferase, and thus mitochondrial metabolism. RealTime-Glo 
438 assay demonstrated that HCT-116 p53+/+ cells presented an impairment of metabolic activity 
439 in comparison to HCT-116 p53-/- upon Compound #3 treatment, especially at the dose of 
440 0.5 µM, confirming the data previously obtained through MTS assay (Figure 1D, right panel 
441 and Table 1 for IC50 values). Interestingly, RealTime-Glo assay revealed that HCT-116 p53-/- 
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442 cells underwent a major loss of metabolic activity compared to HCT-116 p53+/+ cells upon 
443 APX2009 administration in a dose-dependent manner, particularly at the doses of 2.5 µM 
444 and 5 µM (Fig. 1D, right panel and Table 1 for IC50 values). These data demonstrated that 
445 the small difference in metabolic activity that we observed with MTS assay (Fig 1C, top right 
446 panel) was much more apparent when the more sensitive RealTime-Glo assay was used. 
447 in place of the MTS assay. In order to exclude that the toxic effect could be associated with 
448 an alteration of the doubling time of the HCT-116 p53+/+ and p53-/- cell lines, we calculated 
449 it (HCT-116 p53+/+ 38±2.2 h, HCT-116 p53-/- 35±2.4 h) and no difference was observed. This 
450 excludes an alteration of the proliferation index as the cause of the effects on cell viability 
451 between the two cell lines.
452 In order to further validate the specificity of Compound #3 and APX2009 as APE1 inhibitors 
453 in the range of doses used in the present study, we took advantages of CH12F3+/+/∆ and 
454 CH12F3∆/∆/∆ cell lines [66], a recently developed murine cell model containing two and zero 
455 copies of APEX1 alleles, respectively (Fig. 1E, left panel). Both CH12F3 cell lines were 
456 treated with increasing concentrations of Compound #3 or APX2009 for 48 hours and then, 
457 the cellular metabolism of viable cells was measured by using a luminescence-based assay 
458 (CellTiter-Glo), which evaluates the amount of total ATP produced by cells. As shown in Fig. 
459 1E, APE1-endonuclease and -redox inhibitors specifically affect CH12F3+/+/∆ but not 
460 CH12F3∆/∆/∆ cell line, as expected, confirming the high specificity of the inhibitors, under the 
461 experimental conditions used (Table 1 for IC50 values). In the case of the effects of 
462 Fiduxosin, SB206553 and Spiclomazine, their specificity was previously demonstrated by 
463 us [22,44].
464 In conclusion, data obtained indicate that the sensitivity of HCT-116 cells to Compound #3 
465 and APX2009 treatment was dependent on their p53 status. Moreover, the inhibition of 
466 APE1-NPM1 interaction impairs cell metabolism independently of p53 status. Interestingly, 
467 while the toxic effect of Compound #3 was dependent on the expression of p53, a more 
468 toxic effect of APX2009 was apparent in p53 knock-out cells.
469
470 3.2. Inhibition of APE1-endonuclease activity promotes p53 activation
471 We then evaluated whether APE1 inhibition could promote p53 activation. We focused only 
472 on Compound #3 and APX2009, since the APE1-NPM1 inhibitors did not display any 
473 significant difference in terms of biological effects exerted on HCT-116 cell lines. p53 
474 activation is part of DDR triggered by single-strand breaks (SSBs) and double-strand breaks 
475 (DSBs) formation. We determined whether the amount of AP sites and SSBs could be 
476 affected by the treatment with Compound #3 in HCT-116 cell lines. AP sites measurements 
477 (Fig 2A) and comet assay analyses (Fig. 2B and C) clearly demonstrated that Compound 
478 #3 treatment promoted a significant increase of AP sites and SSBs formation in both HCT-
479 116 p53+/+ and HCT-116 p53-/- cell lines independently of the p53 status at both the doses 
480 tested (0.5 µM and 3 µM). The non-significant difference in the levels of AP sites and SSBs 
481 between both HCT-116 cell lines is in agreement with the non-differential expression of 
482 APE1 between the two cell lines used (Fig. S1).
483 In order to get a better understanding of the relationship existing between p53, its gene 
484 target genes and the inhibition of APE1 enzymatic activity in HCT-116 cell lines, we analyzed 
485 the protein and mRNA expression levels of p53 and those of some p53-target genes upon 
486 Compound #3 treatment. In details, HCT-116 p53+/+ and HCT-116 p53-/- cells were treated 
487 with increasing concentrations of Compound #3 (0.25 µM and 0.5 µM) and cells were 
488 collected and tested 48 hours later. These doses, with limited effects on cell viability, allowed 
489 to avoide epiphenomena due to general toxic effects and allowed comparison to data 
490 obtained with those obtained with the redox-inhibitor (see below). Upon the administration 
491 of Compound #3, we analyzed the protein levels of APE1, p53, and p21, one of the major 
492 downstream targets of p53 [47], through Western blotting. We observed a significant 
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493 increase of p53 and p21 protein levels upon Compound #3 administration in HCT-116 p53+/+ 
494 cells only, indicating a p53 activation possibly due as a consequence of cell DDR induction 
495 (Fig. 2D). Moreover, the inhibition of APE1-endonuclease activity did not considerably alter 
496 neither APE1 nor NPM1 protein levels in both cell lines, exerting only slight effects. 
497 Densitometric analysis of p53, p21, APE1, and NPM1 protein levels, normalized to actin 
498 levels, is shown in Fig. 2E. Moreover, to further confirm the unaltered levels of APE1 gene 
499 expression upon Compound #3 treatment, we analyzed its mRNA expression. No 
500 statistically significant changes in APE1 transcript were observed (Fig. S1C), confirming that 
501 the higher sensitivity of HCT-116 p53+/+ cell line to Compound #3 is not due to an impairment 
502 of APE1 expression. Furthermore, to test a possible impact of the activation of the p53 
503 pathway on another known p53-target gene, negatively regulated by p53 and involved in 
504 BER [11,57,67–69], we analyzed the mRNA expression level of DNA Polymerase δ (DNA 
505 Polδ). As it is shown in Fig. 2F, the level of transcripts of DNA Polδ decreased upon 
506 Compound #3 treatment in HCT-116 p53+/+ cells only, in line with p53 induction. These data 
507 support the hypothesis that APE1-endonuclease inhibition causes the functional activation 
508 of p53 protein acting both as a transcriptional activator and repressor of different target 
509 genes. 
510 In order to further support that APE1 inhibition may result in p53 activation, a knockdown 
511 approach, through specific siRNA targeting APE1, was used. As shown in Fig 2G, knock 
512 down of APE1 promoted an increased expression of p53 in HCT-116 p53+/+ cell line, 
513 demonstrating a mutual inverse relationship between APE1 and p53 (Fig. 2G). Finally, to 
514 generalize the stimulatory effect by Compound #3 on p53 expression, we treated two 
515 additional tumor cell lines, i.e. AML2 as a model of acute myeloid leukemia cells [70] and 
516 HCC70 cell line, a triple negative breast cancer cell line [71]. These cell lines harbor a wild-
517 type form [70] and a missense mutation (p.R248Q) [71] of the TP53 gene, respectively. 
518 TP53 p.R248Q is a gain-of-function mutation that causes an aberrant overexpression of the 
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519 p53 protein. AML2 and HCC70 cell lines showed an increased expression of p53 upon 
520 Compound #3 treatment, demonstrating that the activation of p53 upon inhibition of APE1-
521 endonuclease activity could be a generalized phenomenon across different cancer cell lines 
522 (Fig. 2H and I) and not only colon specific. Altogether, these data confirm that APE1-
523 endonuclease inhibitor treatment of different cancer cell lines promotes p53 expression and 
524 its functional induction.
525 DNA damage activating the p53-p21 pathway may lead to cell apoptosis through caspase 
526 activation [47]. Therefore, we performed a caspase activity assay to measure apoptosis 
527 induction by Compound #3 treatment (Fig 2L). After 48 hours of treatment with increasing 
528 concentrations of Compound #3, Apo-ONE assay was used to quantify relative levels of 
529 apoptosis. The treatment with APE1 inhibitor induced the activation of the caspase pathway 
530 in both colon cancer cell lines (Fig. 2L) occurring only at the highest dose (3 µM) of 
531 treatment. However, no differences were apparent between the two cell lines, confirming 
532 that Caspase activation was independent of p53-activation and was present only at highest 
533 dose of treatment with Compound #3. Data not shown also demonstrated that Compound 
534 #3-treatment did not exert any significant differential effect on cell cycle of the two isogenic 
535 HCT-116 cell lines.
536 These experiments, coupled with the metabolic assays, indicate that the inhibition of the 
537 APE1-endonuclease activity promoted a p53-induced response involving mitochondria, 
538 which may explain the higher susceptibility of p53+/+ cell metabolism to Compound #3 
539 treatment in the absence of significant Caspase-3 activation and of differential effects on 
540 cell cycle between the two HCT-116 isogenic cell lines.
541
542 3.3 Inhibition of APE1-redox activity does not affect p53 expression
543 We analyzed whether inhibition of APE1-redox activity could affect p53 expression. We 
544 checked the efficacy of APX2009 treatment on HCT-116 colon cancer cell lines, 
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545 qRT-PCR on the baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known 
546 as Survivin, that was already demonstrated to be a target of APE1-redox function [40]. 
547 Treatment with increasing concentrations of APX2009 (Fig. 3A) promoted a decrease in the 
548 expression levels of BIRC5 transcript in both HCT-116 cell lines (Fig. 3A), in line with 
549 previously demonstrated data on different cell lines [40].
550 To assess whether APE1-redox inhibitor stimulates the p53-pathway, we performed the 
551 same set of experiments, as with Compound #3, but with APX2009. We used APX2009 at 
552 concentrations of 5 µM and 10 µM, that promoted a reduction in cell viability of less than 
553 40% similar to the conditions used with Compound #3 treatment. As shown in Fig. 3B and 
554 C, no differences in p53 and in the expression of the p21 target gene were observed upon 
555 the administration of the redox inhibitor. Moreover, DNA Polδ transcript did not significantly 
556 change following APX2009 administration, in agreement with the lack of any stimulatory 
557 effects by the APE1-redox inhibition on p53 levels (Fig. 3D). Moreover, the caspase activity 
558 assay demonstrated a dose-dependent activation of the caspase pathway indistinctly in both 
559 colon cancer cell lines (Fig. 3E).
560 Taken together, these experiments demonstrate that the inhibition of the APE1-redox 
561 activity does not activate a p53-mediated cell response and this is in agreement with data 
562 on cell metabolism. 
563
564 3.4 Inhibition of APE1-endonuclease activity impairs mitochondrial activity in a p53-
565 dependent manner
566 Data obtained so far, through MTS and RealTime-Glo analyses, point to a major role of the 
567 p53-dependent effect of Compound #3 on cell viability due to metabolic effects associated 
568 with mitochondrial toxicity. In order to better characterize this aspect, we directly analyzed 
569 mitochondrial activity using the Cell Mito Stress Test [72] upon Compound #3 treatment. 
570 Specifically, HCT-116 p53+/+ and HCT-116 p53-/- cell lines were treated with 0.5 µM of 
23
571 Compound #3 for 48 hours and were analysed for mitochondrial respiration. The parameters 
572 of basal oxygen consumption, respiration coupled to ATP production, spare respiratory 
573 capacity and maximal respiration were obtained through oxygen consumption rate (OCR) 
574 profile. As represented in Fig. 4A, OCR profile indicates that Compound #3 impaired the 
575 mitochondrial activity of HCT-116 p53+/+ cells, while the treatment did not significantly alter 
576 the mitochondrial function of HCT-116 p53-/- cells. In particular, the OCR values were 
577 comparable between the two colon cancer cell lines under basal conditions. Interestingly, 
578 Compound #3 treatment affected the majority of the respiratory parameters in a p53-
579 dependent manner (Fig. 4B). Among them, the basal and ATP-coupled respiration was 
580 significantly lower in HCT-116 p53+/+ than the isogenic p53-/- counterpart upon treatment. 
581 Moreover, the spare respiratory capacity and maximal respiration were impaired in HCT-
582 116 p53+/+ treated cells in comparison to the untreated condition. On the other hand, we did 
583 not observe any difference in mitochondrial function in p53-null colon cancer cell line upon 
584 treatment. The OCR profiles of HCT-116 p53+/+ and p53-/- cell lines with Compound #3 at 
585 different concentrations (0.25 µM and 1 µM) are shown in Fig. S2, confirming the obtained 
586 results, particularly at the dose of 1 µM. 
587 Overall, the data obtained suggest that the expression of p53 is responsible for the observed 
588 effects on cell metabolism, upon inhibition of APE1-endonuclease activity, through an 
589 involvement of mitochondrial respiratory function.
590
591 3.5 Inhibition of APE1-endonuclease activity sensitizes p53 expressing cell lines to 
592 MMS treatment
593 Based on the results obtained so far, we analyzed the effect of p53 on cell metabolism in 
594 combination with a genotoxic insult, which is specifically repaired through the enzymatic 
595 activity of APE1 and BER [73]. We used methyl methanesulfonate (MMS), an alkylating 
596 agent generating damages specifically repaired through BER [73]. Experimentally, HCT-116 
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597 cells were treated with increasing concentrations of Compound #3 (0.25 µM and 0.5 µM) for 
598 40 hours and in combination with MMS (range from 200 µM to 600 µM) for additional 8 hours 
599 (Fig. 5). After a total of 48 hours of treatment, cell metabolism was measured using the MTS 
600 assay (Table 1 for IC50 values). The graphs in Fig. 5A-C clearly shows that the two isogenic 
601 cell lines responded similarly sensitive to MMS. Interestingly, when Compound #3 was used 
602 in combination with MMS, the sensitivity to the drug treatment increased (Fig. 5A-C); 
603 however, the p53-null colon cancer cells were significantly less sensitive to combination 
604 treatment than the isogenic counterpart (Table 1 for IC50 values), in particular at the dose of 
605 600 µM of MMS, in agreement with the stimulatory effect of Compound #3 on p53 expression 
606 demonstrated above. 
607 These results suggest that p53-status is essential for cellular resistance to genotoxic stress 
608 upon the inhibition of APE1-endonuclease activity.
609
610 3.6 Inhibition of APE1-endonuclease activity exerts toxic effects on patient-derived 
611 tumor organoids metabolism and is associated with the p53-mutational status
612 In order to further validate the possible opportunity of targeting the APE1-endonuclease 
613 activity in CRC and further supporting our data previously obtained with HCT-116 isogenic 
614 cancer cell lines, we performed targeted experiments by using 3D tumor organoids derived 
615 from three different patients affected by colon cancer (P12, P14 and P16). The molecular 
616 and morphological characterization, obtained through immunofluorescence, is shown in Fig. 
617 6A. Patient-derived tumor organoids were positive for the most common intestinal markers, 
618 such as Ki67 (proliferating cells), OLFM4 (intestinal stem cells), E-Cadherin (intestinal 
619 epithelial cells) and Lysozyme (Paneth cells). Representative images of the molecular 
620 morphology of the patient-derived tumor organoids are shown in Fig. 6B. To check the p53-
621 functional status of these model organoids, genomic DNA was isolated from tumor 
622 organoids and used as a template for next generation sequencing analysis, using the 
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623 Torrent S5 GeneStudio NGS platform. After variant calling filtration and annotation, we 
624 detected a c.586C>T stop-gain mutation (p.R196X) in P14 and a c.524G>A missense 
625 mutation (p.R175H) in P16, the latter being a structural aminoacidic substitution causing a 
626 TP53 gain-of-function and wild-type alleles in P12 (Fig. 6C). All samples did not bear any 
627 pathogenic alteration of APEX1 gene sequence. The western blotting analysis 
628 demonstrated that p53 was expressed in P12 and P16 but not in P14, in agreement with 
629 sequencing data (Fig. 6D). No major differences in APE1 protein expression level were 
630 assessed among tumor organoids (Fig. 6E), with only a mild increase in P14 and P16 with 
631 respect to P12. We treated the different tumor organoids with increasing concentrations of 
632 Compound #3 (range from 0.5 to 5 µM) and cell metabolism was measured by using 
633 RealTime-Glo assay upon 48 hours of treatment. Interestingly, the treatment with APE1-
634 endonuclease inhibitor impaired the cell metabolism of all tumor organoids in a dose-
635 dependent manner but to different extents (Fig. 6F and Table 1 for IC50 values). The 
636 reduction of cell metabolism was observed within a range of 40-65% at the concentration of 
637 5 µM. Interestingly, we observed a different cytotoxic sensitivity of the three tumor organoids 
638 to Compound #3 that was dependent on their p53 status. In particular, tumor organoids 
639 expressing wild-type p53 (P12) and the R175H gain-of-function mutant (P16) were more 
640 sensitive to APE1 inhibition than the P14 null-mutant, in agreement with the data obtained 
641 with the colon cancer cell lines. 
642 Even though the limited number of sample patients, these results indicate that the inhibition 
643 of APE1-endonuclease activity significantly hampers the patients-derived tumor organoids 
644 metabolism and is associated with the p53 mutational status, in agreement with data 
645 obtained with HCT-116 cell lines.
646
647 4. Discussion
648 Human cells are constantly subjected to potentially damaging events to the stability of 
649 nucleic acid, with tens of thousands of DNA lesions occurring per day [74]. The intestinal 
650 tract is exposed to multiple insults coming from metabolic activity of the microenvironment 
651 [75] and from the diet [7], that can lead to mutations or deletions in the DNA of epithelial
652 cells. In the intestinal tract, the involvement of the direct reversal of DNA damage by O6-
653 methylguanine-DNA methyltransferase (MGMT), nucleotide excision repair (NER) and base 
654 excision repair (BER) have been described [7]. Alterations of these repair mechanisms are 
655 clearly associated with tumor development but also represent an emerging ‘Achilles’ heel’ 
656 for the development of new anticancer strategies [76]. Indeed, a dysregulation of BER has 
657 been observed in different tumors, such as breast, liver, melanoma, bladder and colorectal 
658 cancer (CRC) [6,77–81]. In the case of CRC, an increased expression of BER enzymes is 
659 associated with a poor prognosis and contributes to chemoresistance [6]. In particular, 
660 higher levels of N-methylpurine-DNA glycosylase (MPG), 8-oxoguanine-DNA glycosylase 
661 (OGG1), APE1, PARP1, DNA polymerase β (Polβ) and XRCC1 are associated with adverse 
662 outcomes in patients with sporadic CRC [6,81]. Interestingly, the tumor suppressor p53, 
663 frequently mutated in the late stages of CRC [48], is involved in the regulation of DNA 
664 glycosylases (OGG1 and MUTYH) [52,53], APE1 [54,55], Pol β [56] and Pol δ [57] 
665 expression. Generally, upon genotoxic lesions, p53 regulates the expression of DNA repair 
666 genes [68], as in the case of APE1 that is negatively regulated by p53 through modulation 
667 of Sp1 stability [57]. Therefore, impaired p53 results in a loss of transcriptional regulation 
668 thus leading to BER imbalance and genome instability. Moreover, the DNA repair capacity 
669 of BER has been taken into account as a prognostic factor to 5-Fluorouracil (5-FU) treatment 
670 in CRC-affected patients, as demonstrated by a recent publication showing that a good 
671 therapy response is correlated with an observed higher activity of BER in non-malignant 
672 adjacent mucosa and a lower BER activity in tumor tissue [82]. To date, the 
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673 effect of the only APE1-redox inhibitor has been highlighted in different cancer cell lines. For 
674 example, APX3330 inhibits cell growth in tumor endothelium/endothelial progenitor cells 
675 [83], leukemia [31], pancreatic [84,85], breast [86], hepatocellular [87], prostate cancer cells 
676 [88] and colon [23]. It should be noted that APE1-redox inhibitor APX3330 recently
677 completed a cancer Phase I clinical trial (https://clinicaltrials.gov/ct2/show/NCT03375086) 
678 [42,43]. Thus, discovering new drugs able to inhibit the activity of APE1 in a CRC context 
679 could be a promising field in the precision medicine. However, no studies targeting the 
680 APE1-endonuclease activity and its effect on p53 activation have been published. Here, we 
681 demonstrated the anticancer effects of different APE1 inhibitors in colon cancer cells and 
682 their relationship with p53 activation. By using different technical approaches, we observed 
683 a p53-dependent metabolic impairment, impacting on mitochondrial respiratory 
684 mechanisms, of HCT-116 cell lines upon treatment with APE1-endonuclease inhibitor, 
685 proving the effectiveness of the treatments also in a CRC context. It is noteworthy to mention 
686 that the APX2009 redox inhibitor resulted more toxic to p53 knock-out cells than wild-type 
687 counterpart. This observation will need additional studies to understand the molecular basis 
688 for this effect.
689 In our case, the increased p53 level, following the DNA damage (AP site accumulation and 
690 SSBs generation) caused by APE1-endonuclease inhibition, was not associated with any 
691 changes in APE1 mRNA and protein levels, in contrast to what was previously demonstrated 
692 in other papers, in which p53 was demonstrated to negatively regulate APE1 gene 
693 expression [55]. Moreover, we did not observe any p53 stimulation caused by APX2009 
694 treatment, therefore suggesting the possibility to target different APE1 activities by acting 
695 through different response mechanisms either involving the DNA-repair or the redox-
696 functions. We also observed that the inhibition of APE1-endonuclease activity promotes p53 
697 activation not only in colon cancer cells, but also in breast and leukemia cancer cell lines, 
698 suggesting that the APE1 inactivation and the consequent accumulation of DNA damage 
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699 converge toward p53 activation. Thus, the use of APE1-endonuclease inhibitors could be 
700 particularly relevant considering the p53-functional status of the specific tumor.
701 Another relevant finding regards the effect of APE1-endonuclease inhibitor on CRC patient-
702 derived tumor organoids. Our study demonstrates that Compound #3 impairs the viability of 
703 CRC patient-derived organoids in a dose-dependent manner and in a p53-dependent 
704 mutational status, which is in agreement with our findings obtained from cancer cell lines.
705 To our knowledge, the observation that the APE1-endonuclease inhibitor effects are 
706 possibly related to the p53 role on mitochondrial metabolism is extremely important. Besides 
707 cell cycle arrest, apoptosis and senescence, p53 plays an important function also in 
708 mitochondrial respiration [89]. As a regulator, p53 induces the expression of cytochrome c 
709 oxidase 2 (SCO2), ferredoxin reductase (FDXR) and glutamine 2 (GLS2), thus modulating 
710 oxidative phosphorylation and tricarboxylic acid (TCA) cycle [89,90]. Moreover, the 
711 involvement of BER in mitochondrial homeostasis has been extensively demonstrated. 
712 Indeed, p53 regulates mitochondrial BER in removing oxidized bases of the mtDNA 
713 generated by reactive oxygen species (ROS) metabolism [91]. Notably, Compound #3 
714 sensitizes p53-expressing colon cancer cells to genotoxic treatment, such as MMS. Due to 
715 the relevance of APE1 inhibition on mitochondrial functionality in a p53-dependent manner, 
716 we performed additional bioinformatics analyses that clearly pointed to a major role of 
717 mitochondrial toxicity correlated with APE1 functional dysregulation in tumors. It is also 
718 possible that the effect of Compound #3 could be also exerted through inhibition of 
719 mitochondrial APE1 [92–94], whose role is still debated. An important confirmation of the 
720 mitochondrial role of APE1 linking to p53 activation is also supported by our recent findings 
721 (Ayyildiz D. et al., submitted). In fact, when characterizing the APE1 protein-protein 
722 interactome (PPI) in different cancers cells, we found that the differential expression status 
723 of APE1 PPI was clearly associated with bad prognosis signatures in cancers (Ayyildiz D. 
724 et al., submitted). TCGA analyses demonstrated that in CRC, 79% (n=287) of APE1 
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725 resulted in upregulation, while 21% (n=77) of the genes altered in expression were 
726 downregulated (Fig. 7A). Based on the relationship existing between these differentially 
727 expressed interactors, by focusing on their subcellular localizations through functional 
728 enrichment analysis based on GO CC terms, we observed that 24% (n=70) of the 
729 upregulated and 12% (n=9) of the downregulated interactors were mitochondria-associated 
730 proteins (Fig. 7A). The subcellular localizations and enrichment results of these 
731 differentially-regulated physical-interactors of APE1 are shown in Fig. 7B. The enrichment 
732 analysis highlighted pathways that can improve our understanding of the importance of 
733 APE1 for mitochondrial activity. Among them, mitochondrial RNA processing, fatty-acid 
734 oxidation, respiratory complex III and apoptosis represented the most important ones (Fig. 
735 7B). All these processes are essential for cancer metabolism [95,96], as in the case of the 
736 mitochondrial respiratory complex III, that plays a role in CRC progression [97]. Interestingly, 
737 some of these interactors were found to be significantly regulated in our previously published 
738 microarray data [98], such as AK2, CKB, CLIC4, DNAJA1, DUT, HSPA1A, IDH1, KYNU, 
739 MTCH2, SHMT2, SIRT1 and YWHAH (marked in red circle in Fig. 7B). SIRT1, which 
740 regulates BER modulating the acetylation status of APE1 [73], has been found upregulated 
741 in various cancer cell lines, including HCT-116 cell line [99]. The survival signature of the 79 
742 interactors were also confirmed by Kaplan-Meier analysis in TCGA colon cancer dataset 
743 (COAD) and BCAP31, CDKN2A, DUT, NIF3L1 and SHMT2 were associated to poor 
744 prognosis (marked with red star in Fig. 7B). Together, this evidences support our findings, 
745 namely the mitochondrial impairment related to p53 upon Compound #3 treatment. The 
746 experimental data we provide, together with these bioinformatics analyses, support the 
747 hypothesis to target mitochondrial function in cancer cells through APE1-endonuclease 
748 inhibitors. More tailored studies are needed along these lines.
749 In conclusion, our data highlights novel relevant aspects regarding developing new 
750 strategies for targeting BER, and especially APE1 functions, in CRC. Therefore, the 
30
31
751 opportunity to use APE1-endonuclease inhibitors, such as Compound #3, in cancer therapy 
752 should not be underestimated. Finally, greater treatment efficacy and reduced drug 
753 resistance onset mechanisms have been demonstrated when different anti-cancer drugs 
754 are combined together [100], thus the possibility of studying the effects of the different 
755 combination of APE1 inhibitors with well-known chemotherapeutic agents may open new 
756 perspectives in cancer biology research.
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1147 Table
1148
Model used Drug Time (hours) IC50 (
M)
Assay
CH12F3+/+/∆ 1.44
∆/∆/∆CH12F3 1.9
HCT-116 p53+/+ 0.58
HCT-116 p53-/- 0.69
HCT-116 p53+/+ 1.04
HCT-116 p53-/- 1.50
CH12F3+/+/∆ 6.61
∆/∆/∆CH12F3 9.64
HCT-116 p53+/+ 11.7
HCT-116 p53-/- 11.6
HCT-116 p53+/+ 10.0
HCT-116 p53-/- 6.39
HCT-116 p53+/+ 16.1
HCT-116 p53-/- 15.6
HCT-116 p53+/+ n.d. (>100)
HCT-116 p53-/- n.d. (>100)
HCT-116 p53+/+ 30.4
HCT-116 p53-/- 31.2
HCT-116 p53+/+ 721
HCT-116 p53-/- 938
HCT-116 p53+/+ 0.373
HCT-116 p53-/- 0.58
tumor organoid P12 1.36
tumor organoid P14 2.8
tumor organoid P16 0.71
RealTime-Glo
CellTiter
MTS
CellTiter
RealTime-Glo
MTS
RealTime-Glo
MTS
Compound #3 48
Fiduxosin
SB206553
Spiclomazine
MMS
Compound #3
48
8
40 + 8
Compound #3
APX2009
1149 Table 1: List of IC50 values obtained from each model used. The analysis was carried 
1150 out using the Combenefit 2.021 software allowing to calculate the IC50 values for each drug 
1151 tested on the models analyzed. Cell models (cell lines and patient-derived 3D tumor 
1152 organoids), types of assays, drugs and time points are reported. n.d. indicates that the 
1153 goodness of fit value is too low or a standard Hill equation does not correctly account for the 
1154 specific agent used. In some cases, the expected interpolated IC50 value has been reported. 
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1155
1156 Figure legends
1157 Fig. 1. APE1 is overexpressed in colorectal cancer and the inhibition of its 
1158 endonuclease activity triggers p53-mediated effects on cell metabolism.
1159 (A) Gene expression level of APEX1 in the CRC samples of the four CMS classes and
1160 normal controls (CMS1 MSI Immune n=71; CMS2 Canonical n=130; CMS3 Metabolic n=58; 
1161 CMS4 Mesenchymal n=98; control n=42). For left to right, the violin plots illustrate the 
1162 log(FPKM+1) normalized gene expression level in the CMS 1-4 class CRC and normal 
1163 control samples, respectively. (B) Schematic representation of different functions of APE1. 
1164 The specific inhibitors of the different functions of APE1 are also indicated. (C) Western blot 
1165 analysis of p53 and APE1 protein levels in HCT116 p53+/+ and p53-/- cell lines. Actin was 
1166 used as a loading control. MTS assay on HCT-116 p53+/+ and p53-/- cell lines. Cells were 
1167 treated with increasing amounts of APE1 inhibitors (Compound #3, APX2009, Fiduxosin, 
1168 SB206553 and Spiclomazine) at the indicated concentrations for 48 h. Untreated cells were 
1169 treated with DMSO. In graph, the percentage of metabolic activity relative to untreated cells, 
1170 arbitrary set to 100%, is represented. Values are mean±SD (n≥3). (D) RealTime Glo assay 
1171 on HCT-116 p53+/+ and p53-/- cell lines. Cells were treated with increasing amounts of 
1172 Compound #3 or APX2009 for 48 h. Untreated cells were treated with DMSO. In graph, the 
1173 percentage of metabolic activity relative to untreated cells, arbitrary set to 100%, is 
1174 represented. Values are mean±SD (n=3). (E) Western blot analysis of APE1 in CH12F3+/+/∆ 
1175 and CH12F3∆/∆/∆ cell lines. Actin was used as a loading control. CellTiter assay on 
1176 CH12F3+/+/∆ and CH12F3∆/∆/∆ cell lines. Cells were treated with increasing amounts of 
1177 Compound #3 or APX2009 at the indicated concentrations for 48 h. The percentages of 
1178 viable cells relative to untreated cells, arbitrary set to 100%, are represented in graph. 
1179 Values are mean±SD (n=3). Data were evaluated statistically by two-tails Student t-test. 
1180 Resulting p-value is indicated (* p<0.05, ** p<0.01, *** p<0.005).
50
1181
1182 Fig. 2. Inhibition of APE1-endonuclease activity promotes p53 activation.
1183 HCT-116 p53+/+ and p53−/− cell lines were treated with Compound #3 (#3) at the indicated 
1184 concentrations for 48h. Untreated cells were treated with DMSO (A-F, L). (A) The amount 
1185 of abasic (AP) sites was measurement. Values are mean±SD (n=3). (B) Representative 
1186 fluorescence confocal microscope images of in vitro comet assay. Scale bars, 25 μm.  (C) 
1187 Tail moment was analysed for 100 cells at random by OpenComet software. Untreated cells 
1188 was used as reference and set to 1. Values are mean±SD. (D) Western blot analysis of p53, 
1189 p21, APE1 and Nucleophosmin (NPM1) protein levels. Actin was used as a loading control 
1190 (n=3). (E) Densitometric analysis of p53, p21, APE1 and NPM1 protein expression. Levels 
1191 were normalized to actin. Fold change values relative to untreated control cells, arbitrary set 
1192 to 100%, are shown. Values are mean±SD (n=3). (F) Expression level of DNA Polimerase 
1193 δ (DNA Pol δ) was determined by qRT-PCR analysis. DNA Pol δ levels were normalized to 
1194 β-actin. Fold change values relative to untreated control cells, arbitrary set to 1, are shown. 
1195 Values are mean±SD (n=3). (G) HCT116 p53+/+ cell lines silenced for APE1 expression. 
1196 Western blot analysis of p53 and APE1 protein levels. Actin was used as a loading control. 
1197 Fold change values relative to untreated control cells, arbitrary set to 1, are shown. (H and 
1198 I) Western blot analysis of p53 protein levels upon Compound #3 (#3) at the indicated
1199 concentrations of AML2 cell lines treated with for 48 h (H) and HCC70 cell lines treated for 
1200 24 h (I). Actin was used as a loading control. Fold change values relative to untreated control 
1201 cells, arbitrary set to 1, are shown (n=3). (L) Apo-ONE assay was used to quantify relative 
1202 levels of apoptosis. The activities of caspases 3/7 were examined using a fluorescence-
1203 based assay. Untreated control cells were used as reference and set to 100%. Values are 
1204 mean±SD (n=2). Data were evaluated statistically by two-tails Student t-test. Resulting p-
1205 value is indicated (* p<0.05, ** p<0.01).
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1206
1207 Fig. 3. Inhibition of APE1-redox activity does not affect p53 expression. 
1208 HCT-116 p53+/+ and HCT-116 p53 −/− cells were treated with APX2009 (APX) at the indicated 
1209 concentrations for 48h. Untreated cells were treated with DMSO. (A) Expression level of 
1210 BIRC5 was determined by qRT-PCR analysis. BIRC5 levels were normalized to β-actin. 
1211 Fold change expression values relative to untreated cells, arbitrary set to 1, are shown. 
1212 Values are mean±SD (n=3). (B) Western blot analysis of p53, p21, APE1 and 
1213 Nucleophosmin (NPM1) protein levels. Actin was used as a loading control (n=3). (C) 
1214 Densitometric analysis of p53, p21, APE1 and NPM1 protein expression. Levels were 
1215 normalized to actin. Fold change values relative to untreated control cells, arbitrary set to 
1216 100%, are shown. Values are mean±SD (n=3). (D) Expression level of DNA Polimerase δ 
1217 (DNA Pol δ) was determined by qRT-PCR analysis. DNA Pol δ levels were normalized to 
β-
1218 actin. Fold change expression values relative to untreated control cells, arbitrary set to 1, 
1219 are shown. Values are mean±SD (n=3). (E) Apo-ONE assay was used to quantify relative 
1220 levels of apoptosis. The activities of caspases 3/7 were examined using a fluorescence-
1221 based assay. Untreated control cells were used as reference and set to 100%. Values are 
1222 mean±SD (n=3). Data were evaluated statistically by two-tails Student t-test. Resulting p-
1223 value is indicated (* p<0.05, ** p<0.01).
1224
1225 Fig. 4. Inhibition of APE1-endonuclease activity impairs mitochondrial activity in a 
1226 p53-dependent manner.
1227 (A and B) HCT-116 p53+/+ and p53-/- cells were seeded in a Seahorse XF-24 analyzer and 
1228 treated with 0.5 µM of Compund#3 for 48 h. Untreated cells were treated with DMSO. (A) 
1229 Real-time oxygen consumption rate (OCR) was determined during sequential treatments 
1230 with oligomycin (ATP-synthase inhibitor), FCCP (uncoupler of oxidative phosphorylation), 
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1231 rotenone (complex I inhibitor) and antimycin-A (complex III inhibitor). (B) The rates of basal 
1232 respiration, ATP-coupled respiration, spare respiratory capacity and maximal respiration 
1233 were quantified by normalization of OCR level to total protein content. Data represent 
1234 means±SEM (n=3). Data were evaluated statistically by two-tails Student t-test. Resulting 
1235 p-value is indicated (* p<0.05, *** p<0.005).
1236
1237 Fig. 5. Inhibition of APE1-endonuclease activity sensitises p53 expressing cell lines 
1238 to MMS treatment.
1239 MTS assay on HCT-116 p53+/+ and HCT-116 p53-/- cells. Cells were treated with Compound 
1240 #3 (#3) at the indicated concentrations for 40 h and in combination with 200 µM (A), 400 µM 
1241 (B) or 600 µM (C) methyl methanesulfonate (MMS) for additional 8 h. Untreated cells were
1242 treated with DMSO. In graph, the percentage of metabolic activity relative to untreated cells, 
1243 arbitrary set to 100%, is represented. Values are mean±SD (n=3). Data were evaluated 
1244 statistically by two-tails Student t-test. Resulting p-value is indicated (* p<0.05, ** p<0.01).
1245
1246 Fig. 6. Inhibition of APE1-endonuclease activity exerts toxic effects on patient-derived 
1247 tumor organoids metabolism and is associated with the p53 mutational status.
1248 (A) Fluorescence confocal microscope imaging of patient-derived organoids. Patient-
1249 derived organoids were stained with Ki67 (proliferating cells), OLFM4 (intestinal stem cell), 
1250 E-Cadherin (intestinal epithelial cells) or Lysozyme (Paneth cells). F-actin was stained with
1251 Phalloidin. Nuclei were visualized with DAPI. Scale bars, 50 µm (Ki67 and Lysozyme) and 
1252 25 µm (OLFM4 and E-Cadherin). (B) Brightfield representative images of colorectal cancer 
1253 organoids derived from different patients (P12, P14 and P16). Scale bars, 200 µm. (C) TP53 
1254 mutational status in colorectal cancer organoids was assessed by NGS. Patient P12, 
1255 represented by the green box, harboured a wild-type p53, patient P14, represented by the 
53
1256 blue box, beared a stop-gain mutation while patient P16, represented by the orange box, 
1257 harboured a missense one. (D) Western blot analysis of p53 protein level in CRC patient-
1258 derived organoids. The graph shows the densitometric analysis of p53 protein expression 
1259 in patient-derived organoids. Fold change values relative to P12, arbitrary set to 1, are 
1260 shown. Values are mean of 3 measurements±SD. (E) Western blot analysis of APE1 protein 
1261 level in CRC patient-derived organoids. The graph shows the densitometric analysis of 
1262 APE1 protein expression in patient-derived organoids. Fold change values relative to P12, 
1263 arbitrary set to 1, are shown. Values are mean of 3 measurements±SD. (F) RealTime-Glo 
1264 assay on patient-derived tumor organoids. Patient-derived tumor organoids were treated 
1265 with increasing amounts of Compound #3 (range from 0.5 µM to 5 µM) for 48 h. In graph, 
1266 the percentage of metabolic activity relative to untreated organoids, arbitrary set to 100%, 
1267 is represented (n=1). Values are mean of 5 measurements±SD. 
1268
1269 Fig. 7. Differentially expressed interactors of APE1 in colorectal cancer.
1270 (A) Differentially expressed genes (DEGs) coding APE1 interactors in colon cancer (COAD)
1271 are in the middle. Cellular locations of upregulated interactors in upper panel and 
1272 downregulated interactors in lower panel. The colour codes are as follows: green colour for 
1273 up-regulation, orange colour for down-regulation, blue colour for mitochondrial location and 
1274 grey colour for other cellular locations. (B) Representation of DEGs on mitochondrial 
1275 scheme. Grey shaded boxes indicate mitochondrial locations while boxes without any shade 
1276 indicate enriched pathways. Green upside arrows indicate up-regulation while red downside 
1277 arrows indicate down-regulation. Genes that were also regulated in previously published 
1278 microarray data were shown in red circles. Poor prognostic interactors were marked with 
1279 circled skull symbol. 
1280
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1281 Fig. S1. APE1 mRNA and protein levels remain stable in basal condition and upon 
1282 APE1 endonuclease inhibition in colon cancer cell lines. 
1283 (A) Expression level of APE1 were determined by qRT-PCR analysis. APE1 levels were
1284 normalized to β-actin. Fold change expression values relative to HCT-116 p53+/+ cells, 
1285 arbitrary set to 1, are shown. Values are mean±SD (n=3). (B) Densitometric analysis of 
1286 basal APE1 expression. Levels were normalized to actin. HCT-116 p53+/+ cells were used 
1287 as reference and set to 100%. Values are mean±SD (n=6). (C) HCT116 p53+/+ and HCT116 
1288 p53-/- cells were treated with Compound #3 (#3) at the indicated concentration for 48 h. 
1289 Expression level of APE1 were determined by qRT-PCR analysis. APE1 levels were 
1290 normalized to β-actin. Fold change expression values relative to untreated control cells, 
1291 arbitrary set to 1, are shown. Values are mean±SD (n=3).The p-value was calculated using 
1292 Student’s two-tailed t-test. Resulting p-value is indicated (NS, not significant).
1293
1294 Fig. S2. Inhibition of APE1-endonuclease activity impairs mitochondrial activity in a 
1295 p53-dependent manner.
1296 HCT-116 p53+/+ and HCT-116 p53-/- cells were seeded in a Seahorse XF-24 analyzer and 
1297 treated with 0.25 µM (A) and 1 µM (B) of Compound #3 at the indicated concentrations for 
1298 48 h. Untreated cells were treated with DMSO. Real-time oxygen consumption rate (OCR) 
1299 was determined during sequential treatments with oligomycin (ATP-synthase inhibitor), 
1300 FCCP (uncoupler of oxidative phosphorylation), rotenone (complex I inhibitor) and 
1301 antimycin-A (complex III inhibitor). Values are mean of 5 measurements±SD.
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